Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- 08 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 05 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.